
neomycin-polymyxin b-dexamethasone opht brand names and other generic formulations include:
Ak-trol Opht, Cpc Optic Opht, Dexa/neo/poly Opht, Dexacidin Opht, Dexacine Opht, Dexasporin Opht, Dex-gen Opht, Dex-ide Opht, Infa-trol Opht, Infectrol Opht, Maxitrol Opht, Methadex Opht, Neo Poly B Sulf Dex Opht, Neo Poly Dex Opht, Poly-dex Opht, Spectro-max Opht, Storz-n-p-d Opht, W-dnp Opht
cabozantinib oral brand names and other generic formulations include:
Cometriq Oral
neomycin-polymyxin b-dexamethasone opht and cabozantinib oral
neomycin-polymyxin b-dexamethasone opht will decrease the level or effect of cabozantinib oral by altering drug metabolism. Avoid combining cabozantinib with drugs that increase its breakdown. If it is combined with such drugs, increase the cabozantinib dose by 40 mg/day or by 20 mg/day. Resume the previous dose 2-3 days after the interacting drug is stopped.
neomycin-polymyxin b-dexamethasone opht and cabozantinib oral
neomycin-polymyxin b-dexamethasone opht will decrease the level or effect of cabozantinib oral by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid coadministration of cabozantinib with strong CYP3A4 inducers. If a strong CYP3A4 inducer is required, increase cabozantinib dose by 40 mg/day (Cometriq) or by 20 mg/day (Cabometyx). Resume previous dose 2-3 days after strong CYP3A4 inducer discontinued.
Check for more interactions with the Drug Interaction Checker
Drug Interaction Categories
Contraindicated
Never use this combination of drugs because of high risk for dangerous interaction
Serious
Potential for serious interaction; regular monitoring by your doctor required or alternate medication may be needed
Significant
Potential for significant interaction (monitoring by your doctor is likely required)
Minor
Interaction is unlikely, minor, or nonsignificant